Sequenom Granted Continued Listing on Nasdaq | GenomeWeb

NEW YORK, June 28 (GenomeWeb News) - Sequenom has received a letter from Nasdaq's Listing Qualifications Panel stating that it is now compliant with the minimum bid price requirement for continued listing on the Nasdaq National Market, Sequenom said today.

 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.

In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.

Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.

In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.